Live Breaking News & Updates on Clinical Oncology Sponsored

Press release content from Business Wire. The AP news staff was not involved in its creation.
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
April 10, 2021 GMT
BOULDER, Colo. (BUSINESS WIRE) Apr 10, 2021
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced solid tumors in Japanese patients (RUCA-J) will be presented during week one of the American Association for Cancer Research Virtual Annual Meeting (AACR), taking place April 10-15, 2021.
“We remain committed to understanding how Rubraca may benefit patients with cancer, and the data presented at AACR further enhance our understanding in different patient populations and solid tumor types,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “The Phase 1b RAMP data for the co ....

United States , Arpit Rao , Patrickj Mahaffy , Kenji Tamura , Anna Sussman , Lisa Guiterman , Breanna Burkart , National Cancer Center Hospital , Clovis Oncology Inc , National Clinical Trials Network , National Cancer Institute , Alliance For Clinical Trials In Oncology , Alliance For Clinical , Community Research Oncology Program , Exchange Commission , Clinical Research , University Of Minnesota , American Association , Cancer Research Virtual Annual Meeting , Clinical Oncology Sponsored , Genomic Characteristics , Metastatic Castration Resistant Prostate Cancer , Japanese Patients , Previously Treated Advanced Solid , Phasei Clinical , Acute Myeloid Leukemia ,